K22

K22 is an inhibitor of coronavirus RNA synthesis that specifically targets membrane-associated coronavirus RNA synthesis. K22 effectively blocks replication of multiple coronaviruses by inhibiting the critical step of viral replication complex anchoring to host cell membranes to form double-membrane vesicles (DMVs) . K22 exhibits broad-spectrum antiviral activity against diverse coronaviruses, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Feline Coronavirus (FCoV), Mouse Hepatitis Virus (MHV), and Avian Infectious Bronchitis Virus (IBV) [1].